IP Library Granted Patent US 8,952,173
Granted Patent B2
US 8,952,173 · App. 11/913,842 · Granted Feb 10, 2015

Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds

Inventors: Luis Octavio Silva Guisasola (Boecillo-Valladolid, ES); Jorge Martin Juarez (Boecillo-Valladolid, ES)
Assignee: Crystal Pharma, S.A.U.
C07D277/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,952,173
App. No.
11/913,842
Granted
Feb 10, 2015
Kind
B2
Abstract

The invention relates to a novel method for the resolution of the racemic mixture of compound (R,S)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole, or the enrichment of same with in one of its enantiomers, and to intermediate compounds which can be used to perform said method.

Claims (16)

1. A process for the resolution into one of the enantiomers of the racemate of the compound of formula (I)

or for the enrichment of a mixture with any enantiomeric excess of said compound of formula (I), comprising the following steps:

a) reacting said racemate, or said mixture with any enantiomeric excess of the compound of formula (I), with any of the enantiomers of a chiral acid of formula (IV):

wherein R is monosubstituted phenyl or alkylphenyl,

in a polar aprotic solvent and water mixture where said solvent is dimethylformamide; and

b) obtaining, by means of crystallization or fractionated crystallization of the reaction mixture of step a), an optically pure diastereoisomeric mono-salt of general formula (V) or a mono-salt enriched in any of its two possible diastereoisomeric forms of general formula (V):

wherein X is the anion of the salt of the chiral acid of formula (IV).

2. The process according to claim 1 , wherein the chiral acid of formula (IV) is (+)-di-p-toluyl-D-tartaric acid.

3. The process according to claim 1 , wherein the chiral acid of formula (IV) is (−)-di-p-toluyl-L-tartaric acid.

4. The process according to claim 1 , for the isolation of a solid enriched in the (R)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (+)-di-p-toluyl-D-tartrate diastereoisomeric salt (+,+), wherein the compound of formula (IV) is (+)-di-p-toluyl-D-tartaric acid and the solvent and water mixture water content is less than 5% (v/v).

5. The process according to claim 1 , for the isolation of a solid enriched in the (S)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (+)-di-p-toluyl-D-tartrate diastereoisomeric salt (−,+), wherein the compound of formula (IV) is (+)-di-p-toluyl-D-tartaric acid and the solvent and water mixture water content is greater than 5% and less than 40% (v/v).

6. The process according to claim 1 , for the isolation of a solid enriched in the (R)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (−)-di-p-toluyl-L-tartrate diastereoisomeric salt (+,−), wherein the compound of formula (IV) is (−)-di-p-toluyl-L-tartaric acid and the solvent and water mixture water content is less than 20% (v/v).

7. The process according to claim 1 , for the isolation of a solid enriched in the (S)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (−)-di-p-toluyl-L-tartrate diastereoisomeric salt (−,−), wherein the compound of formula (IV) is (−)-di-p-toluyl-L-tartaric acid and the solvent and water mixture water content is greater than 40% and less than 55% (v/v).

8. The process according to claim 1 , comprising an additional isolation step of isolating the other optically pure diastereoisomeric mono-salt of general formula (V), or of a mono-salt enriched in the other diastereoisomeric form of general formula (V):

wherein X is the anion of the salt of the chiral acid of formula (IV).

9. The process according to claim 8 , wherein the additional isolation step of the other mono-salt comprises the addition of water to the mother liquor generated upon isolating the first mono-salt of general formula (V), so as to cause precipitation of the said other mono-salt of general formula (V).

Assignments (2)
MERGER Recorded Feb 28, 2013
From: RAGACTIVES, S.L.U.
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 030011/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2008
From: GUISASOLA, LUIS OCTAVIO SILVA; JUAREZ, JORGE MARTIN
To: RAGACTIVES, S.L.
Reel/Frame 020750/0651 →
Priority Claims (1)
ES 200501103 · May 9, 2005 · national
Continuity (1)
Related Publication 20080194832A1 · Aug 14, 2008